Literature DB >> 28005411

A Mutation in the Dmp1 Gene Alters Phosphate Responsiveness in Mice.

Shoji Ichikawa1, Rita L Gerard-O'Riley1, Dena Acton1, Amie K McQueen1, Isabel E Strobel1, Phillip C Witcher1, Jian Q Feng2, Michael J Econs1,3.   

Abstract

Mutations in the dentin matrix protein 1 (DMP1) gene cause autosomal recessive hypophosphatemic rickets (ARHR). Hypophosphatemia in ARHR results from increased circulating levels of the phosphaturic hormone, fibroblast growth factor 23 (FGF23). Similarly, elevated FGF23, caused by mutations in the PHEX gene, is responsible for the hypophosphatemia in X-linked hypophosphatemic rickets (XLH). Previously, we demonstrated that a Phex mutation in mice creates a lower set point for extracellular phosphate, where an increment in phosphorus further stimulates Fgf23 production to maintain low serum phosphorus levels. To test the presence of the similar set point defect in ARHR, we generated 4- and 12-week-old Dmp1/Galnt3 double knockout mice and controls, including Dmp1 knockout mice (a murine model of ARHR), Galnt3 knockout mice (a murine model of familial tumoral calcinosis), and phenotypically normal double heterozygous mice. Galnt3 knockout mice had increased proteolytic cleavage of Fgf23, leading to low circulating intact Fgf23 levels with consequent hyperphosphatemia. In contrast, Dmp1 knockout mice had little Fgf23 cleavage and increased femoral Fgf23 expression, resulting in hypophosphatemia and low femoral bone mineral density (BMD). However, introduction of the Galnt3 null allele to Dmp1 knockout mice resulted in a significant increase in serum phosphorus and normalization of BMD. This increased serum phosphorus was accompanied by markedly elevated Fgf23 expression and circulating Fgf23 levels, an attempt to reduce serum phosphorus in the face of improving phosphorus levels. These data indicate that a Dmp1 mutation creates a lower set point for extracellular phosphate and maintains it through the regulation of Fgf23 cleavage and expression.
Copyright © 2017 by the Endocrine Society.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28005411      PMCID: PMC5460778          DOI: 10.1210/en.2016-1642

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  21 in total

1.  Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation.

Authors:  Kentaro Kato; Charlotte Jeanneau; Mads Agervig Tarp; Anna Benet-Pagès; Bettina Lorenz-Depiereux; Eric Paul Bennett; Ulla Mandel; Tim M Strom; Henrik Clausen
Journal:  J Biol Chem       Date:  2006-04-25       Impact factor: 5.157

2.  Genomic organization of the human PEX gene mutated in X-linked dominant hypophosphatemic rickets.

Authors:  F Francis; T M Strom; S Hennig; A Böddrich; B Lorenz; O Brandau; K L Mohnike; M Cagnoli; C Steffens; S Klages; K Borzym; T Pohl; C Oudet; M J Econs; P S Rowe; R Reinhardt; T Meitinger; H Lehrach
Journal:  Genome Res       Date:  1997-06       Impact factor: 9.043

3.  Mutational analysis of the PEX gene in patients with X-linked hypophosphatemic rickets.

Authors:  I A Holm; X Huang; L M Kunkel
Journal:  Am J Hum Genet       Date:  1997-04       Impact factor: 11.025

4.  Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling.

Authors:  Aline Martin; Shiguang Liu; Valentin David; Hua Li; Anastasios Karydis; Jian Q Feng; L Darryl Quarles
Journal:  FASEB J       Date:  2011-04-20       Impact factor: 5.191

5.  Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23.

Authors:  Yaacov Frishberg; Nobuaki Ito; Choni Rinat; Yuji Yamazaki; Sofia Feinstein; Itaru Urakawa; Paulina Navon-Elkan; Rachel Becker-Cohen; Takeyoshi Yamashita; Kaori Araya; Takashi Igarashi; Toshiro Fujita; Seiji Fukumoto
Journal:  J Bone Miner Res       Date:  2007-02       Impact factor: 6.741

6.  The Dentin matrix protein 1 (Dmp1) is specifically expressed in mineralized, but not soft, tissues during development.

Authors:  J Q Feng; H Huang; Y Lu; L Ye; Y Xie; T W Tsutsui; T Kunieda; T Castranio; G Scott; L B Bonewald; Y Mishina
Journal:  J Dent Res       Date:  2003-10       Impact factor: 6.116

7.  cDNA cloning of the murine Pex gene implicated in X-linked hypophosphatemia and evidence for expression in bone.

Authors:  L Du; M Desbarats; J Viel; F H Glorieux; C Cawthorn; B Ecarot
Journal:  Genomics       Date:  1996-08-15       Impact factor: 5.736

8.  Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol.

Authors:  R M Harrell; K W Lyles; J M Harrelson; N E Friedman; M K Drezner
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

9.  Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.

Authors:  Itsuro Endo; Seiji Fukumoto; Keiichi Ozono; Noriyuki Namba; Hiroyuki Tanaka; Daisuke Inoue; Masanori Minagawa; Toshitsugu Sugimoto; Mika Yamauchi; Toshimi Michigami; Toshio Matsumoto
Journal:  Bone       Date:  2008-03-05       Impact factor: 4.398

10.  Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets.

Authors:  Uri S Alon; Rachel Levy-Olomucki; Wayne V Moore; Jason Stubbs; Shiguang Liu; L Darryl Quarles
Journal:  Clin J Am Soc Nephrol       Date:  2008-02-06       Impact factor: 8.237

View more
  9 in total

1.  Burosumab Treatment for Autosomal Recessive Hypophosphatemic Rickets Type 1 (ARHR1).

Authors:  Xiuying Bai; Mark Levental; Andrew C Karaplis
Journal:  J Clin Endocrinol Metab       Date:  2022-09-28       Impact factor: 6.134

2.  Defective Mineralization in X-Linked Hypophosphatemia Dental Pulp Cell Cultures.

Authors:  B R Coyac; B Hoac; P Chafey; G Falgayrac; L Slimani; P S Rowe; G Penel; A Linglart; M D McKee; C Chaussain; C Bardet
Journal:  J Dent Res       Date:  2017-09-07       Impact factor: 6.116

Review 3.  New Therapies for Hypophosphatemia-Related to FGF23 Excess.

Authors:  Diana Athonvarangkul; Karl L Insogna
Journal:  Calcif Tissue Int       Date:  2020-06-05       Impact factor: 4.333

4.  Iron Chelation Resulting in Renal Phosphate Wasting.

Authors:  Lynda Cheddani; Thierry Leblanc; Caroline Silve; Nahid Tabibzadeh; Dominique Prié; Jean-Philippe Haymann; Marie-Noëlle Péraldi; Michel Daudon; Paul Meria; Emmanuel Letavernier
Journal:  Kidney Int Rep       Date:  2017-07-29

5.  Osteocytes Enhance Osteogenesis by Autophagy-Mediated FGF23 Secretion Under Mechanical Tension.

Authors:  Huiyue Xu; Meng Xia; Lian Sun; Hua Wang; Wei-Bing Zhang
Journal:  Front Cell Dev Biol       Date:  2022-01-31

6.  The Effects of Inorganic Phosphorus Levels on Phosphorus Utilization, Local Bone-Derived Regulators, and BMP/MAPK Pathway in Primary Cultured Osteoblasts of Broiler Chicks.

Authors:  Tingting Li; Sumei Cao; Xiudong Liao; Yuxin Shao; Liyang Zhang; Lin Lu; Zongping Liu; Xugang Luo
Journal:  Front Vet Sci       Date:  2022-03-22

7.  Osteocyte-specific dentin matrix protein 1 : the role of mineralization regulation in low-magnitude high-frequency vibration enhanced osteoporotic fracture healing.

Authors:  Meng C M Li; Simon K-H Chow; Ronald M Y Wong; Bailing Chen; Jack C Y Cheng; Ling Qin; Wing-Hoi Cheung
Journal:  Bone Joint Res       Date:  2022-07       Impact factor: 4.410

8.  Genetic Knockout and Rescue Studies in Mice Unravel Abnormal Phosphorus Threshold in Hypophosphatemic Rickets.

Authors:  Cheryl P Sanchez; Subburaman Mohan
Journal:  Endocrinology       Date:  2017-03-01       Impact factor: 4.736

Review 9.  Physiological Actions of Fibroblast Growth Factor-23.

Authors:  Reinhold G Erben
Journal:  Front Endocrinol (Lausanne)       Date:  2018-05-28       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.